tablet composition also overcomes the expected loss of crystallinity of efavirenz by adding the lactose extra-granularly while maintaining the dissolution profile.--

IN THE CLAIMS:

Please amend claims 1 as follows:

1. (amended) A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent, wherein efavirenz is crystalline and is from about 1 to about 75% by weight of the total composition of the compressed tablet.

Please add the following new claims 24-41:

24. (new) The compressed tablet as recited in Claim 1, wherein efavirenz is present in an amount of 300 mg.

25. (new) The compressed tablet as recited in Claim 1, wherein efavirenz is present in an amount of 600 mg.

26. (new) A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent, wherein efavirenz is crystalline and is about 50% by weight of the total composition of the compressed tablet.

27. (new) The compressed tablet as recited in Claim 26, wherein efavirenz is present in an amount of about 300 mg.

28. (new) The compressed tablet as recited in Claim 26, wherein efavirenz is present in an amount of about 600 mg.

29. (new) The compressed tablet as recited in Claim 26, wherein the solvent comprises: water, ethanol or mixtures thereof.

30. (new) The compressed tablet as recited in Claim 29, wherein the filler/disintegrant is a microcrystalline cellulose.

31. (new) The compressed tablet as recited in Claim 30, wherein the superdisintegrant is a croscarmellose sodium.

32. (new) The compressed tablet as recited in Claim 31, wherein the croscarmellose sodium is about 5% by weight of the total composition of the compressed tablet.

33. (new) The compressed tablet as recited in Claim 31, wherein the binder is a hydroxypropyl cellulose.

34. (new) The compressed tablet as recited in Claim 33, wherein the surfactant is a sodium lauryl sulfate.

35. (new) The compressed tablet as recited in Claim 34, wherein the filler/compression aid is a lactose hydrous spray dried.

36. (new) The compressed tablet as recited in Claim 35, wherein the lubricant is a magnesium stearate.

37. (new) A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent; wherein efavirenz is crystalline and is from about 1 to about 75% by weight of the total composition of the compressed tablet; and wherein the compressed tablet is prepared via wet granulation in which efavirenz, filler/disintegrant, superdisintegrant, binder, and surfactant are blended intragranularly, and filler/compression aid and lubricant are added extragranularly.

38. (new) The compressed tablet as recited in Claim 37, wherein efavirenz is about 50% by weight of the total composition of the compressed tablet.

39. (new) The compressed tablet as recited in Claim 37, wherein efavirenz is present in an amount of about 300 mg.

40. (new) The compressed tablet as recited in Claim 37, wherein efavirenz is present in an amount of about 600 mg.

41. (new) The compressed tablet as recited in Claim 37, wherein:
the filler/disintegrant is a microcrystalline cellulose;
the superdisintegrant is a croscarmellose sodium;
the binder is a hydroxypropyl cellulose;
the surfactant is a sodium lauryl sulfate;
the filler/compression aid is a lactose hydrous spray dried; and
the lubricant is a magnesium stearate.